Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Nov 1;173(11):1101-1109.
doi: 10.1176/appi.ajp.2016.15081101. Epub 2016 Jul 15.

Right Unilateral Ultrabrief Pulse ECT in Geriatric Depression: Phase 1 of the PRIDE Study

Charles H Kellner  1 , Mustafa M Husain  1 , Rebecca G Knapp  1 , W Vaughn McCall  1 , Georgios Petrides  1 , Matthew V Rudorfer  1 , Robert C Young  1 , Shirlene Sampson  1 , Shawn M McClintock  1 , Martina Mueller  1 , Joan Prudic  1 , Robert M Greenberg  1 , Richard D Weiner  1 , Samuel H Bailine  1 , Peter B Rosenquist  1 , Ahmad Raza  1 , Styliani Kaliora  1 , Vassilios Latoussakis  1 , Kristen G Tobias  1 , Mimi C Briggs  1 , Lauren S Liebman  1 , Emma T Geduldig  1 , Abeba A Teklehaimanot  1 , Sarah H Lisanby  1 ; CORE/PRIDE Work Group  1
Affiliations
Clinical Trial

Right Unilateral Ultrabrief Pulse ECT in Geriatric Depression: Phase 1 of the PRIDE Study

Charles H Kellner et al. Am J Psychiatry. .

Abstract

Objective: The Prolonging Remission in Depressed Elderly (PRIDE) study evaluated the efficacy of right unilateral ultrabrief pulse electroconvulsive therapy (ECT) combined with venlafaxine for the treatment of geriatric depression.

Method: PRIDE was a two-phase multisite study. Phase 1 was an acute course of right unilateral ultrabrief pulse ECT, combined with open-label venlafaxine at seven academic medical centers. In phase 2 (reported separately), patients who had remitted were randomly assigned to receive pharmacotherapy (venlafaxine plus lithium) or pharmacotherapy plus continuation ECT. In phase 1, depressed patients received high-dose ECT (at six times the seizure threshold) three times per week. Venlafaxine was started during the first week of treatment and continued throughout the study. The primary outcome measure was remission, assessed with the 24-item Hamilton Depression Rating Scale (HAM-D), which was administered three times per week. Secondary outcome measures were post-ECT reorientation and safety. Paired t tests were used to estimate and evaluate the significance of change from baseline in HAM-D scores.

Results: Of 240 patients who entered phase 1 of the study, 172 completed it. Overall, 61.7% (148/240) of all patients met remission criteria, 10.0% (24/240) did not remit, and 28.3% (68/240) dropped out; 70% (169/240) met response criteria. Among those who remitted, the mean decrease in HAM-D score was 24.7 points (95% CI=23.4, 25.9), with a mean final score of 6.2 (SD=2.5) and an average change from baseline of 79%. The mean number of ECT treatments to remission was 7.3 (SD=3.1).

Conclusions: Right unilateral ultrabrief pulse ECT, combined with venlafaxine, is a rapidly acting and highly effective treatment option for depressed geriatric patients, with excellent safety and tolerability. These data add to the evidence base supporting the efficacy of ECT to treat severe depression in elderly patients.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.. Remission, Response, and Dropout in a Study of ECT and Venlafaxine in Geriatric Depressiona
aRemission was defined as having a score ≤10 on the 24-item Hamilton Depression Rating Scale (HAM-D) on two consecutive ratings; response was defined as having at least a 50% decrease in HAM-D score from baseline to last assessment.
FIGURE 2.
FIGURE 2.. Trajectory of Observed Mean Scores on the 24-Item Hamilton Depression Rating Scale (HAM-D), by Outcome Group, in a Study of ECT and Venlafaxine in Geriatric Depressiona
aVisits 15–17 were omitted because of small sample sizes (N=3, 2, 1, respectively), resulting in unstable means.
FIGURE 3.
FIGURE 3.
Speed of Remission Among Remitted Patients (N=148) in a Study of ECT and Venlafaxine in Geriatric Depression
See this image and copyright information in PMC

Comment in

References

    1. Ferrari AJ, Charlson FJ, Norman RE, et al.: Burden of depressive disorders by country, sex, age, and year: findings from the Global Burden of Disease Study 2010. PLoS Med 2013; 10:e1001547. - PMC - PubMed
    1. Schulz R, Drayer RA, Rollman BL: Depression as a risk factor for non-suicide mortality in the elderly. Biol Psychiatry 2002; 52:205–225 - PubMed
    1. Conwell Y: Suicide later in life: challenges and priorities for prevention. Am J Prev Med 2014; 47(suppl 2):S244–S250 - PubMed
    1. Mulsant BH, Blumberger DM, Ismail Z, et al.: A systematic approach to pharmacotherapy for geriatric major depression. Clin Geriatr Med 2014; 30:517–534 - PMC - PubMed
    1. Greenberg RM, Kellner CH: Electroconvulsive therapy: a selected review. Am J Geriatr Psychiatry 2005; 13:268–281 - PubMed

Publication types

Substances